Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
09:30am, Tuesday, 24'th Feb 2026
Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study d
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
09:30am, Tuesday, 24'th Feb 2026
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Huda Zoghbi Sells 1,638 Shares
04:48am, Tuesday, 24'th Feb 2026
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) Director Huda Zoghbi sold 1,638 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an ave
Lansforsakringar Fondforvaltning AB publ Has $21.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN
06:05am, Monday, 23'rd Feb 2026
Lansforsakringar Fondforvaltning AB publ increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 3.7% during the undefined quarter, according to its most recent filing wi
Citigroup Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN
04:02am, Monday, 23'rd Feb 2026
Citigroup Inc. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities a
1 No-Brainer Biotech Stock To Buy Today and Never Sell
03:45pm, Saturday, 21'st Feb 2026
This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development.
China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN
06:36am, Friday, 20'th Feb 2026
China Universal Asset Management Co. Ltd. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 13.0% in the undefined quarter, according to the company in its most recent disclosure with
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by CenterBook Partners LP
04:34am, Wednesday, 18'th Feb 2026
CenterBook Partners LP grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 10.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities a
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial
07:08am, Tuesday, 17'th Feb 2026
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by CENTRAL TRUST Co
05:36am, Monday, 16'th Feb 2026
CENTRAL TRUST Co cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchang
Assetmark Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN
05:04am, Monday, 16'th Feb 2026
Assetmark Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 83.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned
Advisors Asset Management Inc. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
04:24am, Monday, 16'th Feb 2026
Advisors Asset Management Inc. reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.7% during the third quarter, according to its most recent 13F filing with the Secu
Caprock Group LLC Takes $1.47 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
04:12am, Sunday, 15'th Feb 2026
Caprock Group LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund pur
Mason Hawkins' Strategic Moves: IAC Inc Sees a 44.15% Increase
06:00pm, Friday, 13'th Feb 2026
Insight into Mason Hawkins (Trades, Portfolio)' Fourth Quarter 2025 Investment Strategy Mason Hawkins (Trades, Portfolio) recently submitted the 13F filing for
